Fluenz

BIOLOGICAL4 trials

Sponsors

University of Bergen, Public Health England, Radboud University Medical Center, Imperial College London

Conditions

Immune ToleranceInfluenzaInnate Immune ResponseLive Attenuated Influenza VaccineTonsillitis, Hypertrophy

Phase 4

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).

CompletedNCT02143882

Public Health EnglandLive Attenuated Influenza Vaccine

Start: 2014-09-30End: 2017-03-31Updated: 2018-01-16

Unknown Phase

Immune Response To Intranasal Influenza Vaccination

Active, not recruitingNCT01866540

University of BergenTonsillitis, Hypertrophy

Start: 2012-10-01End: 2030-12-31Target: 300Updated: 2023-12-06

The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response

CompletedNCT02642237

Radboud University Medical CenterImmune Tolerance, Innate Immune Response

Start: 2015-12-31End: 2018-02-28Updated: 2019-05-14

GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE

RecruitingNCT06620185

Imperial College LondonInfluenza

Start: 2025-04-16End: 2026-01-06Target: 36Updated: 2025-05-02

Related Papers

Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016–2017 and 2017–2018 Influenza Seasons in the United Kingdom

Clinical Infectious Diseases2019-08-0218 citations

Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination

Vaccine2016-10-2434 citations